How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,140 results for

Blood Collection Tube

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Nasotracheal Tube Stenting by Nelaton Catheter in Pediatric Dental Surgery

pharyngeal wall 4- severe epistaxis , large amount of blood in the pharynx impeding nasotracheal intubation and necessitating urgent orotracheal intubation. Secondary Outcome Measures : Histopathology of the endotracheal tube contents after extubation [ Time Frame: immediately after extubation ] after extubation the tube contents will be collected in a 5 ml syringe by using sterile swab then tissues will be separated and will be sent for histopathology , the remnant contents will be sent for microscopy (...) Go to Primary Outcome Measures : incidence and severity of Epistaxis [ Time Frame: immediately after nasotracheal intubation ] An independent anesthesiologist who did not observe the tube insertion will assess the incidence and severity of epistaxis using a laryngoscope immediately after tube passage through the nasal cavity , four grades to evaluate epistaxis 1- no epistaxis 2- mild epistaxis ,blood apparent on the surface of the tube 3-moderate epistaxis pooling of blood on the posterior

2018 Clinical Trials

82. Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Procedure: Tissue from Diagnostic Laparoscopy Procedure: Tissue from Core biopsy Procedure: Interval Debulking Procedure: Peripheral blood Procedure: Ascites collection Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 30 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage (...) of care procedure but research specimens will be collected Procedure: Interval Debulking Standard of Care Research tissue samples will be collected Procedure: Peripheral blood -Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively. Procedure: Ascites collection -A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available. Outcome Measures Go to Primary Outcome Measures

2018 Clinical Trials

83. Endotracheal Tube Placement Using Totaltrack Video Laryngeal Mask Use Versus Macintosh Laryngoscope in Low Risk Patients

Endotracheal Tube Placement Using Totaltrack Video Laryngeal Mask Use Versus Macintosh Laryngoscope in Low Risk Patients Endotracheal Tube Placement Using Totaltrack Video Laryngeal Mask Use Versus Macintosh Laryngoscope in Low Risk Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Endotracheal Tube Placement Using Totaltrack Video Laryngeal Mask Use Versus Macintosh Laryngoscope in Low Risk Patients (VLM) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

84. Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before

2018 Clinical Trials

85. Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

. Progression-free survival [ Time Frame: From start of treatment up to 1 year after completion of study treatment ] Progression-free survival determined by Kaplan-Meier curves. Other Outcome Measures: Pharmacokinetics of mirvetuximab soravtansine and rucaparib in combination Cmax trough concentrations [ Time Frame: predose and post dose at selected times ] Pharmacokinetics determined by analysis of collected blood samples Eligibility Criteria Go to Information from the National Library of Medicine Choosing (...) Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2018 Clinical Trials

86. Small-Volume Tubes to Reduce Anemia and Transfusion

Information provided by (Responsible Party): Population Health Research Institute Study Details Study Description Go to Brief Summary: STRATUS will evaluate the use of small-volume ("soft-draw") blood collection tubes for laboratory testing in reducing anemia and transfusion in intensive care unit patients without significant adverse consequences. This is a simple, cost-neutral intervention that could improve the quality of patient care and reduce the harms of frequent laboratory testing. Condition (...) or disease Intervention/treatment Phase Blood Loss Anemia Device: Small-Volume Blood Collection Tubes Device: Standard-Volume Blood Collection Tubes Not Applicable Detailed Description: Blood sampling can cause significant unnecessary blood loss particularly in the intensive care unit (ICU). Blood loss contributes to anemia which is highly prevalent in the ICU and is associated with major adverse cardiovascular outcomes and death. Red blood cell (RBC) transfusions to correct anemia also have significant

2018 Clinical Trials

87. Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

) performance status of 0, 1 Have recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer (serous, clear cell, endometrioid or mucinous) Patient is willing to wear activity tracking device at least 70% of the time for the duration of the study (9 months) Patient is getting cancer treatment and surveillance visit at Roswell Park Cancer Institute during the study period Patient is willing to participate in quality of life (QOL) questionnaires and blood and stool collection throughout (...) cells in blood, and bacterial composition in gut. Condition or disease Intervention/treatment Phase Fallopian Tube Endometrioid Tumor Fallopian Tube Mucinous Neoplasm Fallopian Tube Serous Neoplasm Ovarian Clear Cell Tumor Ovarian Endometrioid Tumor Ovarian Mucinous Tumor Ovarian Serous Tumor Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Other: Laboratory Biomarker Analysis Device: Monitoring Device Other: Physical Activity Other: Quality

2018 Clinical Trials

88. NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

for new blood cells and blood-forming cells (stem cells) to grow. Giving NY-ESO-1 TCR T cells and stem cells after the conditioning chemotherapy is intended to replace the immune system with new immune cells that have been redirected to attack and kill the cancer cells and thereby improve immune system function against cancer. Giving NY-ESO-1 TCR engineered T cells and HSCs after melphalan may work better in treating participants with ovarian, fallopian tube, or primary peritoneal cancer. Condition (...) NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2018 Clinical Trials

89. Evaluating an Education Program to Reduce Indeterminate QuantiFERON Gold In-Tube Results (PubMed)

emailed a link to an online pretest educational program with a QFT-G blood collection and handling presentation, and a posttest assessment.Of the 332 nurses emailed, 94 (28.4%) voluntarily completed both tests within the 6-month time allotted. The nurses that completed the education program had a significantly higher posteducation test score than on the pretest (70.2% versus 55.3%, p<0.001, effect size=0.82). Improved posttest score was seen in 67.0% of participants. No reduction in the proportion (...) of indeterminate test results was seen overall at HMH in the 6 months after education.A targeted education program was able to successfully increase nurses' knowledge of blood collection and handling procedures for the QFT-G test, but no association was found between the improvement of posttest score and indeterminate QFT-G test results.

Full Text available with Trip Pro

2018 Tuberculosis research and treatment

90. Response to Endotracheal Tube Intubation at Different Time of Fentanyl Given During Induction

Response to Endotracheal Tube Intubation at Different Time of Fentanyl Given During Induction Response to Endotracheal Tube Intubation at Different Time of Fentanyl Given During Induction - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Response to Endotracheal Tube Intubation at Different Time of Fentanyl Given During Induction The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03728686 Recruitment Status : Completed First Posted : November 2, 2018 Last Update Posted : November 6, 2018 Sponsor: Chien

2018 Clinical Trials

91. Is closed thoracic drainage tube necessary for minimally invasive thoracoscopic-esophagectomy? (PubMed)

Is closed thoracic drainage tube necessary for minimally invasive thoracoscopic-esophagectomy? Closed thoracic drainage tube (CTDT) is a conventional treatment after esophagectomy, even after minimally invasive esophagectomy. Here, we report a single-center, retrospective study to explore the safety and necessity of CTDT after thoracoscopic-esophagectomy.From October 2015 and August 2016, 50 patients were enrolled and underwent thoracoscopic-esophagectomy in semi-prone position by same surgical (...) team. Perioperative demographic and surgical parameters, and patients' satisfaction with or without CTDT after thoracoscopic-esophagectomy were collected and analyzed.All eligible patients (18 patients without CTDT and 32 patients with CTDT) were successfully underwent thoracoscopic procedures without conversion to open approach or major intraoperative complications and perioperative death. The two groups, with similar demographic parameters, had no statistically difference in thoracic operation

Full Text available with Trip Pro

2018 Journal of thoracic disease

92. Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Description Go to Brief Summary: This phase I/IIa trial studies the side effects and best dose of a type of specialized immune cell (natural killer cell-like cytotoxic T-lymphocytes (CTLs) (nCTLs) and how well they work when given with a vaccine (alpha-type-1 polarized dendritic cells) in treating patients with stage II-IV ovarian, fallopian tube, or primary peritoneal cancer. nCTLs are immune cells that are isolated from each patient?s blood and "taught" in the laboratory how to recognize (...) Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2018 Clinical Trials

93. Pilot Study of Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube

tubes will also be collected for future research and routine pathology purposes. Condition or disease Intervention/treatment Phase Fallopian Tube Cancer Fallopian Tube Infection Drug: Aspirin 81 mg Early Phase 1 Detailed Description: Subjects in this study will receive low dose aspirin for 14 days before undergoing surgery to remove fallopian tubes removed to determine whether aspirin decreases inflammation in the fallopian tube. Subjects will also submit blood samples at their initial visit (...) with their oncologist, at the time of surgery and at the pre-operative visit to measure inflammation markers and blood counts. A portion of the subject's fallopian tube will be collected for future research studies. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 75 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Surgical Window Pilot Investigation of Short Term

2018 Clinical Trials

94. Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe (PubMed)

nasogastric tube or orally via syringe was compared to administration of the intact capsule in the fasted state, swallowed with water. Blood samples were collected before and after dosing to determine dexlansoprazole pharmacokinetic parameter estimates and plasma concentrations.Similar values for area under the plasma concentration-time curve and observed maximum plasma concentration were achieved when the dexlansoprazole 60 mg capsule was administered as the intact capsule or when the granules were mixed (...) Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe To assess the effect of route of administration on the bioavailability of dexlansoprazole 60 mg delayed-release capsule granules.One open-label, Phase I, single-dose, 3-period crossover study was conducted in healthy adults. The bioavailability of Dexilant® (dexlansoprazole) after dexlansoprazole capsule granules were mixed with water and administered via 16 French

Full Text available with Trip Pro

2018 Clinical and experimental gastroenterology Controlled trial quality: uncertain

95. Active Chest Tube Clearance After Cardiac Surgery is Associated with Reduced Reexploration Rates. (PubMed)

Active Chest Tube Clearance After Cardiac Surgery is Associated with Reduced Reexploration Rates. Ineffective evacuation of intrathoracic fluid after cardiac surgery (retained blood syndrome [RBS]) might increase postoperative complications, morbidity, and mortality. Active tube clearance (ATC) technology using an intraluminal clearing apparatus aims at increasing chest tube drainage efficiency. This study evaluated whether ATC reduces RBS in an all-comers collective undergoing scheduled (...) patients (21%) was higher compared with patients without RBS (3.9%, p < 0.001). Among the RBS components, only reexploration (odds ratio 16, 95% confidence interval: 5.8 to 43, p < 0.001) was relevant for inhospital mortality (ATC 6.8%, control 7.7%; p = 0.71).Active tube clearance is associated with reduced reexploration rates in an all-comers collective undergoing cardiac surgery. Reexploration is the only RBS component relevant for mortality. The ATC effect does not translate into improved overall

2018 Annals of Thoracic Surgery

96. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Patient Version

and ovaries. The doctor or nurse also inserts a lubricated, gloved finger into the rectum to feel for lumps or abnormal areas. Pelvic exam. A doctor or nurse inserts one or two lubricated, gloved fingers of one hand into the vagina and presses on the lower abdomen with the other hand. This is done to feel the size, shape, and position of the uterus and ovaries. The vagina, cervix, fallopian tubes, and rectum are also checked. : A test that measures the level of CA 125 in the blood. CA 125 is a substance (...) , fallopian tube cancer, or primary peritoneal cancer that has recurred. is a PARP inhibitor that is being studied to treat advanced ovarian cancer. are targeted therapy drugs that may the growth of new blood vessels that tumors need to grow and may kill cancer cells. is an angiogenesis inhibitor being studied in the treatment of ovarian cancer. See for more information. New types of treatment are being tested in clinical trials. This summary section describes treatments that are being studied in clinical

2016 PDQ - NCI's Comprehensive Cancer Database

97. Evaluation of a solid matrix for collection and ambient storage of RNA from whole blood. (PubMed)

Evaluation of a solid matrix for collection and ambient storage of RNA from whole blood. Whole blood gene expression-based molecular diagnostic tests are becoming increasingly available. Conventional tube-based methods for obtaining RNA from whole blood can be limited by phlebotomy, volume requirements, and RNA stability during transport and storage. A dried blood spot matrix for collecting high-quality RNA, called RNA Stabilizing Matrix (RSM), was evaluated against PAXgene® blood collection (...) tubes.Whole blood was collected from 25 individuals and subjected to 3 sample storage conditions: 18 hours at either room temperature (baseline arm) or 37°C, and 6 days at room temperature. RNA was extracted and assessed for integrity by Agilent Bioanalyzer, and gene expression was compared by RT-qPCR across 23 mRNAs comprising a clinical test for obstructive coronary artery disease.RSM produced RNA of relatively high integrity across the various tested conditions (mean RIN ± 95% CI: baseline arm, 6.92

Full Text available with Trip Pro

2014 BMC Clinical Pathology

98. Blood Collection From People With Ovarian Cancer

of the chest, abdomen, and pelvis and/or an MRI. For these scans, they will lie in a machine that takes pictures of their body. A small amount of blood (two tubes) will be collected by needle during one visit. Condition or disease Ovarian Cancer Cancer of the Ovary Ovarian Neoplasms Detailed Description: Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines (...) and human tumors implanted into immunocompromised mice. We have shown that monocytes isolated through elutriation at the NIH blood bank and monocytes isolated from anticoagulated peripheral blood from healthy women from the NIH blood bank are equally capable of killing tumor cells. No data have been collected as to whether monocytes from patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer have tumoricidal properties. In addition, native host anti-tumor cell mediated immune mechanisms may

2014 Clinical Trials

99. Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEBâ„¢ Aneurysm Embolization System

Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEBâ„¢ Aneurysm Embolization System Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03379714 Recruitment Status : Withdrawn (Sponsor decision) First Posted

2017 Clinical Trials

100. Biological Collection in Nephrology for the Study of the Links Between Kidney Disease, Immunity System and Cardiovascular Complications

) of the hospital, where the samples are received, techniqued and preserved, and the Center of Nephrology and Renal Transplantation of the hospital. The collection includes blood samples (whole blood, serum, plasma, total blood RNA, PBMC cells), and urine samples (fresh urine). Participation in the collection is particularly recommended for patients who require a medical renal biopsy in the Nephrology Department. Other well-phenotyped patients (well-defined renal disease diagnosis) may also participate (...) : sample Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine. Outcome Measures Go to Primary Outcome Measures : Blood and urinary biomarkers in renal disease [ Time Frame: one day ] biological assay Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>